Online citations, reference lists, and bibliographies.
← Back to Search

On Serotonin And Migraine: A Clinical And Pharmacological Review

M. Ferrari, P. Saxena
Published 1993 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Migraine patients have chronically low systemic 5-HT, predisposing them to develop migrainous headache once an attack has been initiated. Changes in platelet 5-HT content are not causally related, but reflect similar changes at a neuronal level. Stimulation of vascular 5-HT1 receptors, probably located in the vessel wall within the dural vascular bed, may alleviate the headache and associated symptoms, but does not interact with earlier mechanisms within the pathophysiological cascade. These receptors are of an as yet unidentified 5-HT1 subtype, closely resembling, but not identical to 5-HT1D receptors. Activation of these receptors results in vasoconstriction, inhibiting depolarization of sensory perivascular afferents within the trigemino-vascular system and thus stopping the headache. Additional inhibition of the release of vasoactive neuropeptides may be involved, but seems to be of only secondary clinical importance.
This paper references
10.1177/0333102491011S11110
Ergot Alkaloids Reduce Cranial Arteriovenous Shunting In Pigs: No Major Role for 5-Ht1-Like Receptors
M. Boer (1991)
10.1111/j.1476-5381.1990.tb14682.x
Sumatriptan (GR43175) inhibits cyclic‐AMP accumulation in dog isolated saphenous vein
M. Sumner (1990)
Mechanisms of 5 - hydroxy - tryptamine - induced vasodilatation
EJ Mylecharane
10.1046/j.1468-2982.1991.1105207.x
A Double-Blind Comparison of Granisetron and Placebo for the Treatment of Acute Migraine in The Emergency Department
B. Rowat (1991)
Serotonin, migraine and platelets
Fozard (1982)
Basic mechanisms of antimigraine drugs.
J. Fozard (1982)
10.1159/000116762
The safety and tolerability of sumatriptan: an overview.
E. G. Brown (1991)
In vivo and in vitro ultrastructural evidence for stimulation of dura mast cells by neuropeptides
V Dimitriadou (1990)
10.1046/j.1468-2982.1988.0801007.x
The Platelet and The Neuron: Two Cells in Focus in Migraine
R. Malmgren (1988)
The production of migraine and biochemical changes in induced attacks. In: Smith Red Background to migraine
JN Blau (1967)
10.1111/j.1476-5381.1989.tb11965.x
Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5‐HT1‐like or 5‐HT2 receptors
A. H. Bom (1989)
10.1111/j.1526-4610.1979.hed1901014.x
Platelet Serotonin (5‐HT) and 5‐HT Releasing Factor in Plasma of Migrainous Patients
D. Mück-Šeler (1979)
Release of platelet 5 - hydroxytryptamine by plasma taken during and between migraine attacks
A Dvilanski (1976)
10.1212/WNL.39.9.1239
Serotonin metabolism in migraine
M. Ferrari (1989)
Metoclopramide in migrane treatment.
J. Hughes (1977)
10.1046/j.1468-2982.1986.0604205.x
Urinary 5–HIAA in Migraine: Evidence of Lowered Excretion in Young Adult Females
M. Bousser (1986)
10.1002/SYN.890030109
Identification of 5‐hydroxytryptamine1D binding sites in human brain membranes
S. Peroutka (1989)
10.1001/ARCHNEUR.1985.04060040072015
Treatment of cluster headache. A double-blind comparison of oxygen v air inhalation.
L. Fogan (1985)
10.1073/PNAS.86.17.6793
5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system.
S. Molineaux (1989)
10.1016/0014-2999(89)90406-8
Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites.
S. Peroutka (1989)
10.1046/j.1468-2982.1984.0402081.x
Platelet Met-Enkephalin Immunoreactivity and 5–Hydroxytryptamine Concentrations in Migraine Patients: Effects of 5–Hydroxytryptophan, Amitriptyline and Chlorimipramine Treatment
A. Boiardi (1984)
10.1007/BF00541928
Pharmacological actions of the main metabolites of dihydroergotamine
E. Müller‐Schweinitzer (2004)
10.1016/0306-4522(92)90348-6
Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation
V. Dimitriadou (1992)
10.1046/j.1468-2982.1991.1104165.x
Evidence for 5-HT1B/1D Receptors Mediating the Antimigraine Effect of Sumatriptan and Dihydroergotamine
M. G. Buzzi (1991)
10.1111/j.1600-0404.1976.tb04360.x
TOTAL 5‐HYDROXYINDOLES IN BLOOD RELATED to MIGRAINE ATTACKS
J. Berstad (1976)
10.1016/0006-3223(89)90104-2
Seasonal changes of plasma serotonin and related parameters: Correlation with environmental measures
M. J. Sarrias (1989)
10.1001/JAMA.1991.03460210077033
Treatment of acute migraine with subcutaneous sumatriptan.
R. Cady (1991)
10.1111/j.1526-4610.1990.hed3006340.x
Serotonin S2 Receptors and Migraine: A Study With the Selective Antagonist ICI 169,369
P. T. Davies (1990)
Effect of sumatriptan on pial vessel diameter in vivo
Humphrey PPA (1991)
10.1007/978-3-0348-7259-1_24
Contractile 5-HT1D Receptors in Human Brain Vessels
E. Hamel (1991)
10.1159/000116759
A Randomized, Double-Blind Comparison of Sumatriptan and Cafergot in the Acute Treatment of Migraine
P. Humphrey (1991)
10.1016/S0140-6736(83)90286-6
PLATELET SEROTONIN RELEASE IN RHEUMATOID ARTHRITIS: A STUDY IN FOOD-INTOLERANT PATIENTS
C. Little (1983)
10.1002/ANA.410230214
Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
P. J. Goadsby (1988)
10.1046/j.1468-2982.1986.0601051.x
Dihydroergotamine Nasal Spray in the Treatment Of Attacks of Cluster Headache: A Double-Blind Trial Versus Placebo
P. Andersson (1986)
10.1111/j.1476-5381.1991.tb09805.x
Further characterization of the putative 5‐HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater
M. G. Buzzi (1991)
10.1016/0165-6147(89)90238-1
5-HT(1)-like receptor agonists and the pathophysiology of migraine.
P. Saxena (1989)
10.1111/j.1526-4610.1991.hed3104222.x
Cerebral Hyperemia During Spontaneous Cluster Headaches With Excessive Cerebral Vasoconstriction to Hyperoxia
J. Kawamura (1991)
10.1016/0028-3908(91)90165-8
Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion
M. G. Buzzi (1991)
10.1111/j.1476-5381.1989.tb11787.x
The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs
W. Feniuk (1989)
Brain and platelet monoamine oxidase activities in relation to central monoaminergic activity in mice and man
L Oreland (1982)
10.1007/978-1-4757-4577-1
Background to Migraine
J. N. Cumings (1971)
10.1358/DOF.1989.014.09.103408
5-ht3 receptor antagonists
S·希驰库克 (1989)
10.1111/j.1468-2982.1989.tb00069.x
The Pharmacology of the Novel 5-HT1-Like Receptor Agonist, GR43175
P. Humphrey (1989)
10.1046/j.1468-2982.1990.1005213.x
Migraine, Serum Serotonin and Platelet 5–HT2 Receptors
C. A. Ribeiro (1990)
10.1212/WNL.22.4.355
The role of estradiol withdrawal in the etiology of menstrual migraine
B. Somerville (1972)
10.1016/S0006-8993(10)80017-4
5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation
M. G. Buzzi (1992)
Dilemmas in the management of the neurological patient
C. Warlow (1984)
10.1159/000116632
Sumatriptan An Oral Dose-Defining Study
P. Humphrey (1991)
10.1097/00002826-198606000-00003
Ergotamine tartrate dependency: features and possible mechanisms.
J. Saper (1986)
10.1177/03331024870070S6186
Evaluation Of Nasal Tolerability Of Dihydroergotamine Via The Nasal Route
F. Acezat-Mispelter (1987)
10.1002/ANA.410190518
Antimigraine drug interactions with 5‐hydroxytryptamine1A receptors
B. Hiner (1986)
10.1038/jcbfm.1983.9
The Effects of Serotonin on Local Cerebral Blood Flow
J. Grome (1983)
10.1016/0165-6147(90)90058-G
Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain.
G. Pratt (1990)
10.1016/0166-2236(87)90115-9
Cortical spreading depression as a putative migraine mechanism
M. Lauritzen (1987)
10.1159/000158144
Dual action of serotonin on pial arterioles in situ and the effect of propranolol on the response.
L. Edvinsson (1977)
10.1212/WNL.36.7.995
Repetitive intravenous dihydroergotamine as therapy for intractable migraine
N. Raskin (1986)
10.1002/ANA.410330109
The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
P. J. Goadsby (1993)
10.1111/J.1468-2982.1989.TB00071.X
The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175
M. Perren (1989)
10.1016/S0140-6736(77)92604-6
TRANSITORY DECREASE IN PLATELET MONOAMINE-OXIDASE ACTIVITY DURING MIGRAINE ATTACKS
V. Glover (1977)
10.1007/BF00175783
Molecular pharmacology of 5-HT1D recognition sites: Radioligand binding studies in human, pig and calf brain membranes
C. Waeber (2004)
10.1038/clpt.1988.83
Induction of migrainelike headaches by the serotonin agonist m‐chlorophenylpiperazine
T. Brewerton (1988)
10.1016/0165-6147(89)90159-4
Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain.
D. Hoyer (1989)
10.1523/JNEUROSCI.07-12-04129.1987
Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain
S. Markowitz (1987)
99mTc-HMPAO SPECT in migraine attacks without aura and effect of sumatriptan on regional cerebral blood flow. In: Olesen J ed Migraine and other headaches: the vascular mechanism
MD Ferrari (1991)
Basic Mechanisms of Headache
J. Olesen (1988)
Serotonin in mental abnormalities
D. J. Boullin (1978)
10.1111/j.1476-5381.1989.tb11835.x
5‐HT1‐like receptors mediate 5‐hydroxytryptamine‐induced contraction of human isolated basilar artery
A. A. Parsons (1989)
10.1111/j.1476-5381.1990.tb14679.x
The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
M. G. Buzzi (1990)
10.1016/0300-9629(90)90148-l
The Peripheral actions of 5-hydroxytryptamine
J. Fozard (1989)
10.1056/nejm199108013250504
[Treatment of migraine attacks with sumatriptan].
V. Pfaffenrath (1993)
The production of migraine and biochemical changes in induced attacks
JN Blau (1967)
10.1001/JAMA.1985.03350260125047
Dilemmas in the Management of the Neurological Patient
C. Poser (1985)
10.1113/jphysiol.1977.sp012022
Cerebral circulatory and metabolic effects of 5‐hydroxytryptamine in anesthetized baboons.
M. Harper (1977)
The effect of ergotamine on human cerebral blood flow and cerebral arteries. In: Olesen J ed Migraine and other headaches: the vascular mechanisms
P Tfelt-Hansen (1991)
5-HT 3 receptor antagonists
F. King (1989)
10.1111/j.1526-4610.1989.hed2910657.x
Platelet Norepinephrine and Serotonin Balance in Migraine
G. D’Andrea (1989)
10.1111/j.1600-0773.1990.tb00848.x
5-Hydroxytryptamine receptor subtypes.
S. Peroutka (1988)
10.1046/j.1468-2982.1991.1101001.x
Guidelines for Controlled Trials of Drugs in Migraine. First Edition
P. Tfelt-Hansen (1991)
10.1001/ARCHNEUR.1967.00470230096013
Plasma serotonin in migraine and stress.
M. Anthony (1967)
10.1046/j.1468-2982.1991.1103141.x
Kinetics of Platelet 5-Hydroxytryptamine Uptake in Headache Patients
P. Hannah (1991)
10.1016/0306-4522(91)90253-K
Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells
V. Dimtriadou (1991)
10.1007/978-94-009-1912-9_44
Brain 5-HT3 Receptors
G. Kilpatrick (1990)
Migraine headache and blood serotonin levels after administration of zimelidine, a selective inhibitor of serotonin uptake
E Sylvälahti (1979)
Trigemino-vascular connections and mechanisms of vascular headache
MA Moskowitz (1986)
10.1212/WNL.42.8.1522
Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks
J. Caekebeke (1992)
10.1016/0304-3940(88)90307-2
Visualization of a novel serotonin recognition site (5-HT1D) in the human brain by autoradiography
C. Waeber (1988)
10.1093/BRAIN/110.4.917
Focal ischaemia caused by instability of cerebrovascular tone during attacks of hemiplegic migraine. A regional cerebral blood flow study.
L. Friberg (1987)
10.1002/ANA.410230512
Antimigraine drug interactions with serotonin receptor subtypes in human brain
S. Peroutka (1988)
10.1016/0304-3959(91)90052-Y
Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question
M. Ferrari (1991)
10.1016/0022-510X(89)90160-3
Release of platelet Met-enkephalin, but not serotonin, in migraine: A platelet response unique to migraine patients?
M. D. Ferrari (1989)
10.1111/j.1471-4159.1979.tb11050.x
ON THE ELIMINATION OF CENTRALLY FORMED 5‐HYDROXYINDOLEACETIC ACID BY CEREBROSPINAL FLUID AND URINE
M. Aizenstein (1979)
Sumatriptan increases the cranial blood flow velocity during migraine attacks
Caekebeke JFV
Changes in blood serotonin in mental abnormalities. In: Boulin DJ ed Serotonin in mental abnormalities
P Kamoun (1978)
10.1097/00045391-199408000-00012
5-Hydroxytryptamine mechanisms in primary headaches
J. Olesen (1994)
10.1016/0024-3205(79)90121-8
Localization and characterization of phenol sulfotransferase in human platelets.
R. F. Hart (1979)
10.1159/000229194
Biochemical Investigations in Headache: Increase in the Hydroxyindoleacetic Acid Excretion During Migraine Attacks
F. Sicuteri (1961)
10.1007/BF00630292
Investigation of the venoconstrictor effect of 8′ hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man
W. H. Aellig (2004)
10.1056/NEJM199003223221204
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
L. Cubeddu (1990)
10.1016/0166-2236(86)90137-2
The pharmacology and function of 5-HT3receptors
B. Richardson (1986)
10.1002/ANA.410280213
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
P. J. Goadsby (1990)
10.1111/j.1526-4610.1986.hed2604168.x
A Controlled Study of Dihydroergotamine in the Treatment of Acute Migraine Headache
M. Callaham (1986)
Changes in blood serotonin in mental abnormalities
P Kamoun
10.1002/ANA.410290116
Localization of 3H‐Dihydroergotamine‐binding sites in the cat central nervous system: Relevance to migraine
P. J. Goadsby (1991)
10.1016/0165-6147(89)90061-8
5-HT1C receptor activation: a key step in the initiation of migraine?
J. Fozard (1989)
10.1111/j.1476-5381.1991.tb12158.x
Contractile 5‐HT1 receptors in human isolated pial arterioles: correlation with 5‐HT1D binding sites
E. Hamel (1991)
99 mTc - HMPAO SPECT in migraine attacks without aura and effect of sumatriptan on regional cerebral blood flow
Ferrari
The effect of ergotamine on human cerebral blood flow and cerebral arteries
P Tfelt-Hansen
10.1016/0736-4679(92)90247-Q
Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group.
L. Milne (1991)
10.1016/0014-2999(88)90335-4
Identification of 5-HT3 binding sites in rat spinal cord synaptosomal membranes.
S. Glaum (1988)
10.1111/j.1476-5381.1989.tb11828.x
Characterization of 5‐HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5‐HT1‐like receptor agonist
H. Connor (1989)
DIHYDROERGOTAMINE NASAL SPRAY. AUTHOR'S REPLY
H. Gijsman (1995)
10.1161/01.STR.15.6.1021
Inhibition by Ketanserin Of Serotonin Induced Cerebral Arteriolar Constriction
J. Thompson (1984)
10.1001/ARCHNEUR.1989.00520470041024
Platelet serotonin metabolism and ultrastructure in migraine.
G. D'andrea (1989)
10.1177/0333102489009S1016
Neuropeptide Release from Sensory Fibres of Guinea Pig Cerebral Venous Sinuses and Dorsal Spinal Cord: Relevance for Headache Study
P. Geppetti (1989)
10.1002/SYN.890040212
GR 43175: A preferential 5‐HT1D agent in monkey and human brains as shown by autoradiography
C. Waeber (1989)
10.1038/330746A0
Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding
G. Kilpatrick (1987)
10.1126/SCIENCE.3875898
Distinct monoamine oxidase A and B populations in primate brain.
K. Westlund (1985)
The production of migraine and biochemical changes in induced attacks
JN Blau (1967)
10.1073/PNAS.83.15.5731
Calcitonin gene-related peptide: functional role in cerebrovascular regulation.
J. McCulloch (1986)
10.1016/0140-6736(91)90005-A
Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan
L. Friberg (1991)
10.1111/j.1476-5381.1988.tb11630.x
GR43175, a selective agonist for the 5‐HT1‐like receptor in dog isolated saphenous vein
P. Humphrey (1988)
10.1111/j.1526-4610.1980.hed2005235.x
The Biochemistry of Migraine
G. Bruyn (1980)
10.1212/WNL.39.11.1514
Sensitivity and specificity of transcranial Doppler ultrasonography in the diagnosis of vasospasm following subarachnoid hemorrhage
M. Sloan (1989)
Le 5 - HIAA arinaire : signification at application aux antimigraineux . In : Meyer P , Albin H , Jaillon P , Lhoste F eds Les antimigraineux
JL Elghozi (1985)
Portielje JEA. Release of platelet MET-enkephalin, but not serotonin, in migraine
MD Ferrari (1989)
10.1177/0333102489009S10193
Further Studies on the Mechanism of the Antimigraine Action of Sumatriptan
P. P. A. Humphrey (1989)
10.1046/j.1468-2982.1985.0504223.x
Warning Symptoms in Migraine: Characteristics and Therapeutic Implications
J. Waelkens (1985)
10.1136/jnnp.35.4.505
5-Hydroxytryptamine levels and platelet aggregation responses in subjects with acute migraine headache
B. Hilton (1972)
The serotonin/norepinephrine-link in brain. II. Role of serotonin in the regulation of beta adrenoceptors in the low agonist affinity conformation.
D. D. Gillespie (1988)
10.1111/j.1526-4610.1991.hed3104228.x
5‐Hydroxtryptamine 1D Receptor Agonism Predicts Antimigraine Efficacy
V. Anastasia (1991)
10.1111/j.1476-5381.1991.tb12152.x
Vascular 5‐HT1‐like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5‐HT1A or 5‐HT1D subtype
M. Perren (1991)
10.1111/j.1526-4610.1976.hed1602058.x
PLASMA FREE FATTY ACIDS AND PROSTAGLANDIN E1 IN MIGRAINE AND STRESS
M. Anthony (1976)
5-HT and 5-HIAA in body fluids of migraine and tension headache patients
Ferrari (1992)
In vivo and in vitro ultrastructural evidence for stimulation of dura mast cells by neuropeptides
V Dimitriadou (1990)
10.1016/0028-3908(90)90061-U
In vivo effects of sumatriptan (GR 43175) on extracellular levels of 5-HT in the guinea pig
A. Sleight (1990)
5-Hydroxytryptamine (5-HT)-induced endothelium-dependent relaxation of pig coronary arteries is mediated by 5-HT receptors similar to the 5-HT1D receptor subtype.
P. Schoeffter (1990)
10.1007/978-3-0348-7259-1_42
The Vasoconstrictor Action of Sumatriptan on Human Isolated Dura Mater
P. Humphrey (1991)
Urinary excretion of biogenic amines in migraine and tension headache
Ferrari
Drug treatment of migraine.
K. Heathfield (1961)
10.1159/000116760
Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group.
P. Humphrey (1991)
10.1001/ARCHSURG.1940.01210040002001
EXPERIMENTAL STUDIES ON HEADACHE: PAIN-SENSITIVE STRUCTURES OF THE HEAD AND THEIR SIGNIFICANCE IN HEADACHE
B. S. Ray (1940)
10.1007/BF00635900
The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects
H. Curran (2004)
10.1126/SCIENCE.482930
Serotonin neurons project to small blood vessels in the brain.
J. Reinhard (1979)
10.1113/jphysiol.1977.sp012023
Effects of 5‐hydrooxytryptamine on pial arteriolar calibre in anaesthetized cats
A. Harper (1977)
10.1046/j.1468-2982.1990.1005207.x
Lack of Antinociceptive Activity of Sumatriptan in Rodents
M. Skingle (1990)
10.1111/j.1476-5381.1991.tb12173.x
Role of 5‐HT1‐like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan
Marinus O. Boer (1991)
10.1016/0165-6147(91)90583-E
5-HT receptors in human and animal cerebrovasculature.
A. Parsons (1991)
10.1111/j.1526-4610.1976.hed1601016.x
SEROTONIN (5HT) IN MIGRAINE: LEVELS IN WHOLE BLOOD IN AND BETWEEN ATTACKS
W. Rydzewski (1976)
10.1111/j.1526-4610.1990.hed3002052.x
Arterial Stenosis in Migraine: Spasm or Arteriopathy?
S. Solomon (1990)
10.1111/j.1526-4610.1972.hed1202062.x
EXCRETION OF FREE AND CONJUGATED 5‐HIAA AND VMA IN URINE AND CONCENTRATION OF 5‐HIAA AND HVA IN CSF DURING MIGRAINE ATTACKS AND FREE INTERVALS
P. Kangasniemi (1972)
10.1161/01.RES.70.6.1313
Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles.
E. P. Wei (1992)
Does ergotamine work for migraine ?
D Thrush
Fenfluramine headache: a biochemical and monoamine receptorial human study. In: Sicuteri Fed Headache: new vistas
E Del Bene (1977)
First clinical study of the selective 5 - HT 3 antagonist , granisetron ( BRL 43694 ) , in the acute treatment of migraine
Couturier EGM (1991)
10.1016/0006-8993(85)90255-0
Serotonergic innervation of cat cerebral arteries
E. Marco (1985)
10.2165/00003088-198510040-00004
Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster Headache
V. Perrin (1985)
10.1055/S-2007-1017361
Anatomical features and physiological properties of central serotonin neurons.
H. Baumgarten (1985)
10.1136/jnnp.29.1.85
Excretion of 5-hydroxyindolyl acetic acid (5HIAA) in migraine.
G. Curzon (1966)
10.1111/j.1526-4610.1974.hed1403149.x
THE EFFECTS OF RESERPINE INJECTION ON METHYSERGIDE TREATED CONTROL AND MIGRAINOUS SUBJECTS
J. Carroll (1974)
10.1152/PHYSREV.1992.72.1.165
Structure and function of the brain serotonin system.
B. Jacobs (1992)
10.1159/000116758
Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group.
P. Humphrey (1991)
10.3949/ccjm.59.4.434-b
Migraine and Other Headaches: the Vascular Mechanisms
M. Meziane (1992)
The production of migraine and biochemical changes in induced attacks. In: Smith Red Background to migraine
JN Blau (1967)
A randomized , double - blind comparison of sumatriptan and cafergot in the acute treatment of migraine . The multinational oral sumatriptan and cafergot comparative study group
Saper (1991)
10.1111/J.1526-4610.1991.HED3105296.X
First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache
E. Couturier (1991)
10.1111/j.1526-4610.1987.hed2708435.x
Ergotamine Dependency‐ a Review
J. Saper (1987)
10.1111/j.1526-4610.1983.hed2306258.x
Brainstem Influences on the Cephalic Circulation: Experimental Data From Cat and Monkey of Relevance to the Mechanism of Migraine
J. Lance (1983)
10.1016/0006-2952(84)90424-6
Serotonin-releasing effects of substituted piperazines in vitro.
D. Pettibone (1984)
Urinary excretion of biogenic amines in migraine and tension headache. In: Rose FC ed New advances in headache research
MD Ferrari (1989)
5-Hydroxytryptamine induced contraction of rabbit and feline isolated basilar arteries
AA Parsons (1990)
Mechanisms of 5 - hydroxy - tryptamine - induced vasoconstriction
W Feniuk
A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.
(1991)
10.1136/BMJ.285.6347.1009
Severe headache and disturbed liver function during treatment with zimelidine.
J. Sommerville (1982)
10.1016/0024-3205(82)90492-1
Met-enkephalin immunoreactivity in blood platelets.
A. D. Di Giulio (1982)
10.7326/0003-4819-32-2-350_1
Headache and other head pain
H. Wolff (1972)
10.1016/0014-2999(89)90311-7
Evidence for the presence of 5-HT1-like receptors in rabbit isolated basilar arteries.
A. A. Parsons (1989)
10.1046/j.1468-2982.1989.0901053.x
Cerebrospinal Fluid (CSF) Investigations in Migraine
K. Kovács (1989)
10.1111/j.1471-4159.1990.tb02319.x
Relationship Between Serotoninergic Measures in Blood and Cerebrospinal Fluid Simultaneously Obtained in Humans
M. J. Sarrias (1990)
Fluctuation of 5-hydroxy-indole compounds in the urine of migrainous patients.
Z. Deanovic (1975)
10.1016/0028-3908(84)90091-1
Neuronal 5-HT receptors in the periphery
J. Fozard (1984)
10.1038/clpt.1992.202
Psychoactivity and abuse potential of sumatriptan
J. Sullivan (1992)
Morphological effects of electrical trigeminal ganglion stimulation (ETG) on intra- and extracranial vessels
MG Buzzi (1990)
10.1007/978-3-0348-7259-1
Serotonin: Molecular Biology, Receptors and Functional Effects
J. Fozard (1991)
Migraine and other headaches : the vascular mechanisms
J. Olesen (1991)
10.1093/BRAIN/88.5.997
Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects.
D. A. Curran (1965)
10.1016/0304-3940(86)90250-8
Demonstration of monoamine oxidase type B in serotonergic and type A in noradrenergic neurons in the cat dorsal pontine tegmentum by an improved histochemical technique
K. Kitahama (1986)
10.5694/j.1326-5377.1972.tb93040.x
THE MECHANISMS UNDERLYING MIGRAINE 1
M. Anthony (1972)
10.1111/j.1526-4610.1982.hed2205207.x
Platelet Activity in Migraine
Giovanni D' Andrea (1982)
10.1159/000116756
The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan.
P. A. Fowler (1991)
Dihydroergotamine nasal spray. In: Ferrari MD, Lataste X eds New trends in clinical neurology series: migraine and other headaches
X. Lataste (1989)
Fenfluramine headache : a biochemical and monoamine receptorial human study
E DelBene (1977)
Cluster
MA Moskowitz
10.1111/j.1526-4610.1988.hed2809584.x
Cluster Headache: Evidence for a Pathophysiologic Focus in the Superior Pericarotid Cavernous Sinus Plexus
M. Moskowitz (1988)
Intra- and extracraniovascular nociceptive mechanisms and the pathogenesis of headpain
MA Moskowitz (1988)
10.1111/j.1600-0447.1987.tb02923.x
Citalopram versus maprotiline: A controlled, clinical multicentre trial in depressed patients
J. M. Bouchard (1987)
Amine turnover in migraine.
M. Anthony (1975)
10.1007/BF00169206
The pharmacological properties of the presynaptic serotonin autoreceptor in the pig brain cortex conform to the 5-HT1D receptor subtype
E. Schlicker (2004)
10.1002/ANA.410240607
Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches
K. Saito (1988)
10.1038/306055A0
Central serotonergic nerves project to the pial vessels of the brain
L. Edvinsson (1983)
10.1046/j.1468-2982.1988.0802083.x
Neurogenically Mediated Plasma Extravasation in Dura Mater: Effect of Ergot Alkaloids: A Possible Mechanism of Action in Vascular Headache
S. Markowitz (1988)
10.1046/j.1468-2982.1985.0502079.x
Effects on Migraine Headache of MDL 72,222, an Antagonist at Neuronal 5-HT Receptors. Double-Blind, Placebo-Controlled Study
C. Loisy (1985)
10.1007/BF00244401
Serotonin release from blood platelets in multiple sclerosis
E. Caspary (2004)
10.1016/0024-3205(85)90406-0
Serotonin in body fluids: characterization of human plasmatic and cerebrospinal fluid pools by means of a new HPLC method.
F. Artigas (1985)
10.1016/0304-3959(76)90009-9
Release of platelet 5-hydroxytryptamine by plasma taken from patients during and between migraine attacks
A. Dvilansky (1976)
10.1161/01.CIR.79.1.116
Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology.
E. K. van den Berg (1989)
10.1111/j.1749-6632.1990.tb16912.x
Serotonin and Migraine
P. A. Humphrey (1990)
10.1111/j.1526-4610.1991.hed3108525.x
The Treatment of Cluster Headache With Repetitive Intravenous Dihydroergotamine
P. Mather (1991)
10.1161/01.STR.19.12.1466
Transcranial Doppler measurements of the middle cerebral artery. Effect of hematocrit.
L. Brass (1988)
10.1016/0140-6736(91)90666-D
Oral sumatriptan in acute migraine
P. Goadsby (1991)
Le 5-HIAA arinaire: signification at application aux antimigraineux
JL Elghozi (1985)
10.1007/BF00445552
Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium
F. Artigas (2004)



This paper is referenced by
10.1517/13543784.4.4.283
Section Review—Central & Peripheral Nervous Systems: Current and Future Therapies for Migraine
M. Gross (1995)
10.1016/j.ijdevneu.2010.02.007
Early-life treatment of antiserotonin antibodies alters sensitivity to serotonin receptors, nociceptive stimulus and serotonin metabolism in adult rats
S. Bhanja (2010)
10.3164/JCBN.33.95
Serotonin and Its Metabolite; 5-Hydroxyindoleacetic Acid in Neurophysiology of Headache
M. TalaatAbdelAziz (2003)
10.1007/s40122-020-00180-6
Sleep Disorders and Headache: A Review of Correlation and Mutual Influence
E A Korabelnikova (2020)
Genetics in the identification of molecular pathogenic mechanisms of familial migrane.
Maria J Castro (2011)
10.1046/j.1468-2982.1997.1705561.x
A Clinical Review of the Adaptive Role of Vasopressin in Migraine
V. Gupta (1997)
10.3988/jcn.2010.6.1.27
Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial
Heui-Soo Moon (2010)
10.1017/CBO9781139206952.002
Epidemiology of the psychiatric comorbidities of headache
K. Mullin (2010)
10.1111/j.1526-4610.2009.01553.x
Single Nucleotide Polymorphisms of the Serotonin Transporter Gene in Migraine – An Association Study
B. Bayerer (2010)
10.1016/j.jchemneu.2017.06.002
Nitroglycerin increases serotonin transporter expression in rat spinal cord but anandamide modulated this effect
Gábor Nagy-Grócz (2017)
10.1046/j.1526-4610.1999.3910716.x
Fluoxetine for Migraine Prophylaxis: A Double‐Blind Trial
C. C. d’Amato (1999)
10.1016/S0304-3959(99)00017-2
Nociceptive neurons in the rat caudal trigeminal nucleus respond to blood plasma perfusion of the subarachnoid space: the involvement of complement
A. Ebersberger (1999)
10.1016/B978-0-444-52910-7.00001-5
Alternating hemiplegia of childhood.
Sujay M Kansagra (2013)
10.1007/s00415-011-6064-3
Evaluation of contributing factors to restless legs syndrome in migraine patients
S. Suzuki (2011)
Posttraumatic Stress Symptoms and Pain: Examining Models of Co-Occurrence with Twin Analyses
S. Mostoufi (2015)
10.1007/s00415-012-6725-x
Psychiatric comorbidities of episodic and chronic migraine
D. Buse (2012)
10.1046/j.1526-4610.1998.3807534.x
Plasticity of 5‐HT2A Serotonin Receptor in Patients With Analgesic‐Induced Transformed Migraine
A. Srikiatkhachorn (1998)
10.1016/S1098-3597(01)90035-3
Pathophysiology, epidemiology, and impact of migraine.
N. Mathew (2001)
10.1586/14737175.5.5.653
Migraine: new treatment options from molecular biology
A. Stam (2005)
10.1111/j.1468-2982.2006.01212.x
Tryptophan Depletion Increases Nausea, Headache and Photophobia in Migraine Sufferers
P. Drummond (2006)
10.2174/1871527313666140414120956
Disentangling the intricacies of migraine: a review.
Priti Girotra (2014)
A cross-sectional paediatric pilot study of migraine, eating behaviours and adiposity
S. Singh (2000)
10.1523/JNEUROSCI.17-24-09545.1997
Repression of the Calcitonin Gene-Related Peptide Promoter by 5-HT1 Receptor Activation
P. Durham (1997)
10.1111/j.1468-2982.2006.01099.x
Exteroceptive Suppression of Masseter Muscle Activity in Juvenile Migraineurs
F. Ebinger (2006)
Drug and Alcohol Dependence
X. Vi (2012)
10.2217/FNL.12.80
Emerging genomic biomarkers in migraine
Saras Menon (2013)
10.1101/477935
Relating excitatory and inhibitory neurochemicals to visual perception: a magnetic resonance study of occipital cortex between migraine events
Y. M. Chan (2018)
10.1111/j.1526-4610.1994.hed3409497.x
Double‐Blind Trial of Fluoxetine: Chronic Daily Headache and Migraine
J. Saper (1994)
10.1046/j.1468-2982.1998.1804174.x
Dopamine and Migraine: A Review of Pharmacological, Biochemical, Neurophysiological, and Therapeutic Data
A. Mascia (1998)
10.1016/B978-012252687-9/50042-5
Vitamin D Control of the Calcitonin Gene in Thyroid C Cells
A. Russo (2005)
Avaluació de gens de susceptibilitat a formes comunes de migranya
R. Castiñeira (2009)
10.1111/j.1468-2982.2009.01939.x
Migraine and Systemic Vascular Comorbidities
Michel Aubé (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar